RESEARCH PROGRESS OF GLOMERULAR ENDOTHELIAL CELL-PODOCYTE INTERACTION IN DN PATIENTS

被引:1
|
作者
Wan, Xiaoyun [1 ,2 ]
Zhang, Fang [1 ,2 ]
Liu, Chao [1 ,2 ]
机构
[1] Nanjing Univ Tradit Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing 210028, Jiangsu, Peoples R China
[2] Jiangsu Prov Acad Tradit Chinese Med, Nanjing 210028, Jiangsu, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2020年 / 36卷 / 06期
关键词
DN; endothelial cell; podocyte; interaction; DIABETIC-NEPHROPATHY; MESANGIAL CELL; INJURY; EXPRESSION; ALBUMINURIA; DYSFUNCTION; FRAMEWORK; MODEL;
D O I
10.19193/0393-6384_2020_6_592
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic Nephropathy (DN) is one of important pathogeneses resulting in endstage renal disease, seriously affects patients' living quality and threatens life safety. Deeply exploring DN pathogenesis and seeking a more effective treatment method to improve patients' clinical prognosis have become a hot issue in the medical field. The early report holds that podocyte damage has close relations with DN occurrence and development. Recent studies verify that glomerular endothelial cell damage also participates in DN progress. Podocytes and glomerular endothelial cells have many same signal regulation paths, so their interaction has been proven to be a potential important mechanism of DN onset. After DN patients' podocytes are damaged, the secretion of multiple signal molecules including VEGF and Ang-1 is abnormal. Meanwhile, damaged glomerular endothelial cells can synthesize and secrete HGF, IGFBPs and other cytokines which will also influence podocyte functions, thus leading to the changes in the structure and function of podocytes to different degrees. Based on the above evidence, exploring the interaction between glomerular endothelial cells and podocytes has important value for further specifting DN pathogenesis and determining a better treatment strategy.
引用
收藏
页码:3737 / 3742
页数:6
相关论文
共 45 条
  • [41] Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.
    Gruenwald, V.
    Karakiewicz, P. I.
    Bavbek, S. E.
    Miller, K.
    Machiels, J. H.
    Lee, S.
    Larkin, J. M. G.
    Bono, P.
    Rha, S. Y.
    Castellano, D. E.
    Blank, C. U.
    Knox, J. J.
    Hawkins, R.
    Yuan, R. R.
    Rosamilia, M.
    Booth, J. L.
    Bodrogi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO PROGRESS AFTER INITIAL VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (VEGFR-TKI) THERAPY: UK RESULTS FROM THE REACT TRIAL ON BEHALF OF THE UK REACT INVESTIGATORS
    Chowdhury, S.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 271 - 272
  • [43] Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG) 1016
    Ikeda, Satoshi
    Kato, Terufumi
    Ogura, Takashi
    Sekine, Akimasa
    Oda, Tsuneyuki
    Masuda, Noriyuki
    Igawa, Satoshi
    Katono, Ken
    Otani, Sakiko
    Yamada, Kouzo
    Saito, Haruhiro
    Kondo, Tetsuro
    Hosomi, Yukio
    Nakahara, Yoshiro
    Nishikawa, Masanori
    Utumi, Keiko
    Misumi, Yuki
    Yamanaka, Takeharu
    Sakamaki, Kentaro
    Okamoto, Hiroaki
    BMC CANCER, 2018, 18
  • [44] Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
    Satoshi Ikeda
    Terufumi Kato
    Takashi Ogura
    Akimasa Sekine
    Tsuneyuki Oda
    Noriyuki Masuda
    Satoshi Igawa
    Ken Katono
    Sakiko Otani
    Kouzo Yamada
    Haruhiro Saito
    Tetsuro Kondo
    Yukio Hosomi
    Yoshiro Nakahara
    Masanori Nishikawa
    Keiko Utumi
    Yuki Misumi
    Takeharu Yamanaka
    Kentaro Sakamaki
    Hiroaki Okamoto
    BMC Cancer, 18
  • [45] Phase II study of bevacizumab, cisplatin and docetaxel plus maintenance bevacizumab as first line treatment for patients with advanced non-squamous non-small cell lung cancer (n-Sq NSCLC) combined with exploratory analysis of circulating endothelial cells (CEC): Thoracic Oncology Research Group(TORG)1016
    Nakahara, Y.
    Kato, T.
    Masuda, N.
    Oshita, F.
    Hosomi, Y.
    Nishikawa, M.
    Kaburagi, T.
    Okamoto, H.
    Morita, S.
    Watanabe, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S831 - S831